Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...

BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...

BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...

Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...

The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

View BridgeBio Pharma, Inc. (BBIO) current and estimated P/E ratio data provided by Seeking Alpha.

BridgeBio Pharma Reports Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients BridgeBio Pharma, Inc. (Nasdaq: NASDAQ:BBIO) today shared positive results from the Japan ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...